Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.
Lövgren T, Sarhan D, Truxová I, Choudhary B, Maas R, Melief J, Nyström M, Edbäck U, Vermeij R, Scurti G, Nishimura M, Masucci G, Karlsson-Parra A, Lundqvist A, Adamson L, Kiessling R. Lövgren T, et al. Among authors: edback u. Cancer Immunol Immunother. 2017 Oct;66(10):1333-1344. doi: 10.1007/s00262-017-2029-4. Epub 2017 Jun 10. Cancer Immunol Immunother. 2017. PMID: 28601925 Free PMC article.
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.
Lövgren T, Wolodarski M, Wickström S, Edbäck U, Wallin M, Martell E, Markland K, Blomberg P, Nyström M, Lundqvist A, Jacobsson H, Ullenhag G, Ljungman P, Hansson J, Masucci G, Tell R, Poschke I, Adamson L, Mattsson J, Kiessling R. Lövgren T, et al. Among authors: edback u. Oncoimmunology. 2020 Jul 11;9(1):1792058. doi: 10.1080/2162402X.2020.1792058. Oncoimmunology. 2020. PMID: 32923156 Free PMC article. Clinical Trial.
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, Edbäck U, Brage SE, Lundqvist A, Masucci GV, Hansson J, Kiessling R. de Coaña YP, et al. Among authors: edback u. Oncotarget. 2017 Mar 28;8(13):21539-21553. doi: 10.18632/oncotarget.15368. Oncotarget. 2017. PMID: 28423487 Free PMC article. Clinical Trial.
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.
Backlund E, Yang M, Grozman V, Masucci G, Falkenius J, Eriksson H, Jovanovic B, Hammarlund K, Isacsson U, Radu C, Abel E, Karlsson K, Palanco Zamora R, Wersäll P, Edbäck U, Wickström S, Darai Ramqvist E, Egyhazi Brage S, Kiessling R, Viktorsson K, Franzén B, Lewensohn R, Olofsson Bagge R, Ullenhag GJ, Ny L, Lindberg K, Helgadottir H. Backlund E, et al. Among authors: edback u. Acta Oncol. 2022 Jul;61(7):869-873. doi: 10.1080/0284186X.2022.2079959. Epub 2022 May 31. Acta Oncol. 2022. PMID: 35638255 No abstract available.
Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, Buttò S, Gaines H, Imami N, Gotch F, Lori F, Lisziewicz J, Sandström E, Hejdeman B. Gudmundsdotter L, et al. Among authors: edback u. Vaccine. 2011 Jul 26;29(33):5558-66. doi: 10.1016/j.vaccine.2011.01.064. Epub 2011 Feb 5. Vaccine. 2011. PMID: 21300092
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G; HIV Immunogenicity Study 01/02 Team. Sandström E, et al. J Infect Dis. 2008 Nov 15;198(10):1482-90. doi: 10.1086/592507. J Infect Dis. 2008. PMID: 18808335 Free PMC article. Clinical Trial.